Physician profile
Michaela Murphy
NPI 1972124956
$2,464.94
in general payments reported to CMS, 2019-2025
30 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $747 · 2022: $548 · 2023: $344 · 2024: $413 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.08 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $303.45 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $227.16 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.05 | 2022-2025 | |
| Esperion Therapeutics, INC. | $165.63 | 2021-2022 | |
| Lilly USA, LLC | $148.21 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $116.98 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $105.75 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $90.63 | 2022 | |
| Glaxosmithkline, LLC. | $90.17 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $88.03 | 2021 | |
| Abbott Laboratories | $79.45 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $71.49 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $60.20 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $58.94 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $45.64 | 2021-2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $33.28 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $30.74 | 2023 | Veozah |
| Daiichi Sankyo INC. | $24.68 | 2021 | |
| Gilead Sciences, INC. | $21.57 | 2021 | |
| Sequel Med Tech, LLC | $20.42 | 2025 | Twiist |
| Sumitomo Pharma America, INC. | $19.83 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $19.45 | 2021 | |
| Dynavax Technologies Corporation | $18.94 | 2023 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2025 | Jardiance |
| Ibsa Pharma INC. | $18.11 | 2025 | Tirosint, Flector, Licart |
| Renalytix Ai, INC. | $17.53 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Astrazeneca Pharmaceuticals Lp | $15.40 | 2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.83 | 2023 | Cycloset |
| Takeda Pharmaceuticals U.S.A., INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.